SARS-CoV-2 not likely to increase the incidence of type 1 diabetes in children

NewsGuard 100/100 Score

More children and adolescents than usual developed type 1 diabetes in Finland in the first 18 months of the coronavirus pandemic. According to a recently completed study, the cause was not the novel coronavirus, but altered environmental factors.

The incidence of type 1 diabetes increased globally during the coronavirus pandemic. The PEDIA research group of the University of Helsinki has investigated the phenomenon and its causes in children in Finland.

"The mechanisms of the increase in the incidence of diabetes have been unclear, and there has been discussion on whether the increase results from a direct effect of SARS-CoV-2 infection or other simultaneously altered environmental factors," says Professor Mikael Knip, who headed the study.

According to the study, the incidence of type 1 diabetes increased in children in Finland by 16% in the first 18 months of the pandemic. However, very few children or adolescents who developed type 1 diabetes had SARS-CoV-2 antibodies indicating a past infection.

According to the researchers, the increase in the incidence of type 1 diabetes in the early stages of the pandemic is not likely to have been caused directly by coronavirus. Instead, it may be related to the society-wide lockdown in the pandemic period and the resulting social isolation.

"According to what is known as the biodiversity hypothesis, microbial exposure and infections in early childhood can boost the protection against autoimmune diseases. The reduction in contacts in connection with the societal lockdown significantly reduced acute infections in children, which may have increased the risk of developing diabetes," Knip explains.

The results were published in the Lancet Diabetes & Endocrinology journal.

Is the increase in the incidence of pediatric diabetes temporary?

In the study, the incidence of type 1 diabetes in Finns under 15 years of age was compared to three preceding reference periods of the same duration. SARS-CoV-2 antibodies in children with type 1 diabetes were analyzed in collaboration with Professor Olli Vapalahti's research group. Among the 785 children and adolescents diagnosed with type 1 diabetes in the pandemic period, infection-induced SARS-CoV-2 antibodies were found in only five individuals, i..e. lessr than 1%.

The matter must be investigated further to find out what has happened to the incidence of type 1 diabetes since the lifting of the lockdown in summer 2021 and the subsequent increase in the number of coronavirus infections in the population."

Professor Olli Vapalahti

Registers are important sources of data

"The study was based on data from the Finnish Pediatric Diabetes Register," says Mikael Knip, the Principal Investigator in charge of the register.

Since 2002, data and samples from the newly diagnosed children and their family members have been collected in this national register. The register, maintained by HUS Helsinki University Hospital, covers more than 90% of the patients who have developed diabetes.

"The register is globally unique including both data and biological samples and provides irreplaceable data for research," Knip concludes.

Journal reference:

Knip, M., et al. (2023). SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study. The Lancet Diabetes & Endocrinology.


  1. Valerie Collins Valerie Collins United States says:

    Antibodies live only 3-6 months. So using antibodies from an infection over a year old is not a sound way to determine past SARS infection.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants